Vivasure Medical announced today that it launched a development program for its PerQseal Blue investigational product.
Galway, Ireland-based Vivasure designed PerQseal Blue for sutureless and fully absorbable large-bore venous vessel closure following percutaneous cardiovascular procedures, including transcatheter mitral valve repair/replacement (TMVR) and transcatheter tricuspid valve repair/replacement (TTVR).
According to a news release, the company based the PerQseal Blue on its PerQseal closure device that currently holds European approval for use in femoral arteries.
The newly initiated development program was first initiated in 2020 with a €2.5 million grant from the European Innovation Council Accelerator. Vivasure said that no sutureless options for venus closure after TMVR or TTVR procedures currently exist, which would make PerQseal Blue the first.
PerQseal Blue consists of an intravascular patch designed to seal the vessel from the inside, returning the vein to its natural state.
“We’re thrilled to introduce PerQseal Blue to our product development portfolio as a potential new option specifically for large-bore venous closure following percutaneous cardiovascular procedures,” Vivasure Medical CEO Andrew Glass said in the release. “We plan to advance our venous program to the clinical stage in 2022 with the initiation of a study to evaluate and optimize PerQseal Blue.”